Themes - Pharmaceutical Technology

Adcendo and Multitude ink ADC deal potentially worth $1bn

Phalguni Deswal — Tue, 20 Aug 2024 17:27:33 +0000

Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.

Phanes acquires second FDA orphan designation for bispecific antibody

Phalguni Deswal — Mon, 19 Aug 2024 13:35:33 +0000

PT217 has received orphan drug designations from the FDA for the treatment of neuroendocrine carcinoma in addition to small cell lung cancer.

How clinical trials can use AI responsibly and effectively

elsie — Thu, 15 Aug 2024 15:29:03 +0000

Strong measures must be in place to safeguard confidential patient data when deploying AI to optimise clinical trial translations.

Era of ADCs: Pharma companies innovate to stand out in a buzzing market

Akosua Mireku — Mon, 12 Aug 2024 09:49:47 +0000

As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.

GERTEIS

Fri, 09 Aug 2024 08:30:00 +0000

GERTEIS specialises in the design, development and production of premium roller compactors and dry granulation systems for the pharmaceutical industry.

BioNTech exits PD-L1 development with Genmab as Q2 revenues drop

Akosua Mireku — Mon, 05 Aug 2024 15:35:38 +0000

BioNTech has given Genmab full control of their joint PD-L1 therapy program, as it recovers from Q2 losses.

Rejuvenate and SAS partner to harness AI for age-related diseases

Jenna Philpott — Fri, 02 Aug 2024 10:42:46 +0000

LOTTE BIOLOGICS’ East Syracuse Pharmaceutical Manufacturing Facility, US

Wed, 31 Jul 2024 13:30:00 +0000

LOTTE BIOLOGICS, a contract development and manufacturing organisation based in South Korea, uses its facility in East Syracuse, New York, for the process development and manufacturing of biologics.

MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine

Vishnu Priyan — Thu, 25 Jul 2024 08:07:26 +0000

The UK MHRA has authorised Pfizer-BioNTech’s adapted Comirnaty vaccine against the JN.1 Covid-19 subvariant for adults and children.

The potential of 3D printing in drug development and delivery

GlobalData Thematic Intelligence — Wed, 24 Jul 2024 15:41:49 +0000

3D printing is replacing traditional prototype development approaches across various industries, and use in healthcare is increasing fast.